JNCCN 360 - Non-Small Cell Lung Cancer

Editor:

David S. Ettinger, MD, FACP, FCCP

Advertisement

Advertisement

Suresh S. Ramalingam, MD, on Clinical Implications of Using Nivolumab Plus Ipilimumab in First-Line NSCLC

Edward B. Garon, MD, on Capmatinib in METex14-Mutated Advanced NSCLC: Expert Perspective

Julia K. Rotow, MD, on Concurrent Osimertinib Plus Gefitinib in First-Line Treatment of NSCLC

Recent

COVID-19 and Lung Cancer: Proactive Measures for Screening Patients

Osimertinib Given Breakthrough Therapy Designation for EGFR-Mutated Lung Cancer

ctDNA Clearance and Savolitinib Plus Osimertinib in MET-Amplified Lung Cancer

Survival Update With Bevacizumab Plus Erlotinib in Certain Patients With NSCLC

Published

Medical Literature

First-line Osimertinib and Bevacizumab Treatment in Metastatic EGFR-Mutant Lung Cancer

Third-Generation EGFR Tyrosine Kinase Inhibitor in Lung Cancer

Pneumonitis in Patients Treated With Chemotherapy or Immunotherapy

COVID-19 and Lung Cancer: Focus on ALK/ROS1 Inhibitors

Ongoing

Advanced Non-Small Cell Lung Ccancer Patient Management Simulator

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Lung Cancer

Time to Tailor NSCLC RT to Spare the Immune System?

Visiting Professors: Lung Cancer Edition, Issue 1, 2019

Available

Clinical Trials

Yale Cancer Center / Smilow Cancer Hospital

Mayo Clinic Cancer Center

University Hospitals Seidman Cancer Center

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

NCCN Resources

Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.